Co-Diagnostics Statistics
Co-Diagnostics (0A50) Stock Statistics & Valuation Metrics
Total Valuation
Co-Diagnostics has a market cap or net worth of $2.36M. The enterprise value is $7.56M.
- Market Cap
- $2.36M
- Enterprise Value
- $7.56M
Share Statistics
Co-Diagnostics has 10,512,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,512,190
- Owned by Insiders
- 0.92%
- Owned by Institutions
- 2.24%
Financial Efficiency
Co-Diagnostics’s return on equity (ROE) is -2.27 and return on invested capital (ROIC) is -138.31%.
- Return on Equity (ROE)
- -2.27
- Return on Assets (ROA)
- -1.90
- Return on Invested Capital (ROIC)
- -138.31%
- Return on Capital Employed (ROCE)
- -1.48
- Revenue Per Employee
- 5,412.948
- Profits Per Employee
- -407.79K
- Employee Count
- 115
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.22
Valuation Ratios
The current PE Ratio of Co-Diagnostics is -0.01. Co-Diagnostics’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 1.98
- PB Ratio
- 0.15
- Price to FCF
- -0.06
- Price to Operating Cash Flow
- -0.05
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Co-Diagnostics had revenue of 622.49K and earned -46.90M in profits. Earnings per share was -35.25.
- Revenue
- 622.49K
- Gross Profit
- 400.11K
- Operating Income
- -31.28M
- Pretax Income
- -48.51M
- Net Income
- -46.90M
- EBITDA
- -47.41M
- Earnings Per Share (EPS)
- -35.25
Cash Flow
In the last 12 months, operating cash flow was -26.88M and capital expenditures -307,267, giving a free cash flow of -27.19M billion.
- Operating Cash Flow
- -26.88M
- Free Cash Flow
- -27.19M
- Free Cash Flow per Share
- -4.33
Dividends & Yields
Co-Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1615.17%
- Earnings Yield
- -3349.00%
Stock Price Statistics
- Beta
- 1.20
- 52-Week Price Change
- -97.72%
- 50-Day Moving Average
- 0.81
- 200-Day Moving Average
- 2.10
- Relative Strength Index (RSI)
- 23.58
- Average Volume (3m)
- 57.47K
Important Dates
Co-Diagnostics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Co-Diagnostics as a current ratio of 3.87, with Debt / Equity ratio of 5.99%
- Current Ratio
- 3.87
- Quick Ratio
- 3.59
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 0.22
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Co-Diagnostics has paid -1.62M in taxes.
- Income Tax
- -1.62M
- Effective Tax Rate
- 0.03
Enterprise Valuation
Co-Diagnostics EV to EBITDA ratio is -0.05, with an EV/FCF ratio of -0.09.
- EV to Sales
- 2.95
- EV to EBITDA
- -0.05
- EV to Free Cash Flow
- -0.09
- EV to Operating Cash Flow
- -0.09
Balance Sheet
Co-Diagnostics has $714.80K in cash and marketable securities with $1.56M in debt, giving a net cash position of -$849.70K billion.
- Cash & Marketable Securities
- $714.80K
- Total Debt
- $1.56M
- Net Cash
- -$849.70K
- Net Cash Per Share
- -$0.08
- Tangible Book Value Per Share
- $0.35
Margins
Gross margin is -9.47%, with operating margin of -3415.85%, and net profit margin of -5527.61%.
- Gross Margin
- -9.47%
- Operating Margin
- -3415.85%
- Pretax Margin
- -5580.41%
- Net Profit Margin
- -5527.61%
- EBITDA Margin
- -5453.23%
- EBIT Margin
- -5563.51%
Analyst Forecast
The average price target for Co-Diagnostics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $4.00
- Price Target Upside
- 1654.39% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 28.89%
- EPS Growth Forecast
- 34.53%

